AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 201 min read$BBIO

Kumar Neil sold $840K of BBIO (indirect holdings)

Kumar Neil (Chief Executive Officer) sold 10,000 indirectly-held shares of BridgeBio Pharma, Inc. (BBIO) at an average of $84.03 ($83.86–$85.65, $0.84M total) across 3 trades on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published Aug 20, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBIO
Bearish
medium confidence
Mentioned
$BBIO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIOBearishLow
01

Why it matters

The disclosed sale reduces insider ownership but is consistent with a pre-arranged 10b5-1 plan, limiting interpretive weight.

02

Market read

Insider sell is a modest data point; traders may watch for any price reaction but no major market shift expected.

03

What to watch

Potential tax planning or liquidity needs unrelated to company outlook.

Relevance 4/10Novelty 4/10Timing: filing date 2026-08-20

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$BBIOBearishMedium confidence
Context

CEO Kumar Neil sold 10,000 shares for $840K via a 10b5-1 plan, reducing his stake to 505,686 shares.

Expected impact

Possible modest dip in intraday trading as market digests the insider sale.

Evidence & confidence

Sale size is under $1M and typical for 10b5-1 plans; impact likely limited but could trigger short-term sell pressure.

Market effects

Sector

Minimal; biotech sector unlikely to be affected by a single insider sale.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale may be routine under a pre-arranged plan, not indicating negative fundamentals.

Key entities

  • Company
    BridgeBio Pharma, Inc.

    Biotech firm developing therapies for rare diseases.

  • Person
    Kumar Neil

    Chief Executive Officer of BridgeBio Pharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBIO insider trading history →

Related articles

AUG 19
$BBIOMedAI 8/10

BridgeBio (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q2 2026 revenue of $243.7M, up from $110.6M last year, driven by Attruby sales. Net loss was $152.2M, down from $181.9M. The company has $1.7B in cash, with three potential product launches planned. FDA accepted NDAs for BBP-418 and Encaleret, with target action dates in late 2026 and 2027, respectively. Management expects improving operating performance and potential profitability in 2027.

fool.com3 min
AUG 10
$BBIOMedAI 8/10

[BBIO Q2 2026 Earnings Call] Attruby Sales Hit $222M, Surge 120%, as BridgeBio Maps ‘Launch 2.0’ with $1.7B War Chest — BigGo Finance

BridgeBio Pharma (BBIO) reported Q2 2026 Attruby net product revenue of $222.4M, up from $71.5M a year earlier, and total revenue up 120% to $243.7M. Management said it has $1.7B cash after a $1B preferred equity deal. The company discussed CARDIO-TTRansform failure, regulatory progress on three NDAs, and expects breakeven toward 2027.

finance.biggo.com7 min
AUG 10
$BBIOMedAI 8/10

BridgeBio Pharma, Inc. (BBIO): Results of Operations and Financial Condition

BridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians i

SEC EDGAR 8-K7 min